Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma (NASDAQ: STRO) is a clinical-stage biopharmaceutical company pioneering next-generation oncology therapeutics through its proprietary cell-free XpressCF® platform. This page provides centralized access to official news, including clinical trial updates, strategic partnerships, and financial developments.
Investors and researchers will find timely updates on the company’s innovative antibody drug conjugates (ADCs) and bispecific antibody programs. Content categories include clinical milestones, regulatory filings, collaboration announcements, and manufacturing advancements.
Bookmark this page to stay informed about Sutro’s progress in developing precision oncology treatments and its role in advancing cell-free therapeutic innovation. Check regularly for verified updates directly from the company and trusted sources.
Sutro Biopharma (NASDAQ: STRO) announced its Phase 1 dose-escalation trial results for STRO-001, an antibody-drug conjugate targeting CD74 in Non-Hodgkin Lymphoma (NHL), during the virtual ASH Annual Meeting. With 21 NHL patients treated, preliminary data show:
- 90% treatment-emergent adverse events were grade 1 or 2.
- 1 complete response and 2 partial responses in patients with diffuse large B-cell lymphoma.
- Stable disease observed in certain patients with follicular and marginal zone lymphoma.
The study continues to explore the 3.5 mg/kg dose level.
Sutro Biopharma (NASDAQ: STRO) provided a clinical update on STRO-002, an antibody-drug conjugate targeting ovarian cancer. The Phase 1 trial achieved enrollment of 39 patients, with significant results: 10 out of 31 evaluable patients meeting RECIST response criteria, including 1 complete response. Disease control was observed in 74% at 12 weeks and 58% at 16 weeks. The treatment was well-tolerated, with most adverse events being mild. Next steps include randomizing dose levels for expanded patient treatment starting January 2021 and evaluating broader patient populations.
Sutro Biopharma (NASDAQ: STRO) announced the appointment of Jon M. Wigginton, M.D. to its Board of Directors on December 1, 2020. Dr. Wigginton brings over 25 years of experience in clinical oncology and drug development, with previous leadership roles at Bristol Myers Squibb and MacroGenics. His expertise in immuno-oncology is expected to enhance Sutro's clinical pipeline of antibody drug-conjugates, including STRO-001 and STRO-002. The addition of Dr. Wigginton comes at a critical time as Sutro advances its proprietary technology and aims to expand its therapeutic reach.
Sutro Biopharma (NASDAQ: STRO) will host a live webcast on Dec. 3, 2020, at 5pm ET to update on the Phase 1 study of STRO-002, a targeted ADC for ovarian cancer. This follows the data cut-off of Oct. 30, 2020. Principal Investigators, Dr. Lainie P. Martin and Dr. Wendel Naumann, will present findings from the study. The trial is registered under NCT03748186 and aims to evaluate the safety and effectiveness of STRO-002. The webcast registration link is available on Sutro's website.
Sutro Biopharma (NASDAQ: STRO) announced the appointments of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations, enhancing its leadership team. Landa brings 20 years of regulatory experience from Amgen, while Chang has over 15 years in investor relations, previously with Solebury Trout. CEO Bill Newell and CMO Arturo Molina highlighted these appointments as vital for advancing Sutro's clinical pipeline and public presence. Sutro continues to focus on oncology therapeutics with promising products in development, including STRO-001 and STRO-002.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in four virtual conferences scheduled from November to December 2020. Key details include:
- Stifel Virtual Healthcare Conference: Nov. 16, at 3:20 PM ET.
- Jefferies Virtual London Healthcare Conference: Nov. 19, at 12:35 PM ET.
- Piper Sandler 32nd Annual Healthcare Conference: Dec. 1-3, with discussions available from Nov. 23.
- Evercore ISI HealthCONx Conference: Dec. 3, at 10:30 AM ET.
Webcasts will be available through the company’s Investor Relations website.
Sutro Biopharma reported its Q3 2020 financial results, highlighting a revenue of $17.8 million for the quarter, up from $12.3 million in Q3 2019. Total cash and marketable securities reached $202.4 million, a significant increase from $133.5 million at the end of 2019. The company is advancing its clinical trials for STRO-001 and STRO-002, with positive interim data presented at recent conferences. Sutro also recognized a $17.1 million net income, primarily from an unrealized gain on Vaxcyte common stock.
Sutro Biopharma (NASDAQ: STRO) released interim Phase 1 safety and efficacy data for STRO-002, an anti-folate receptor alpha antibody drug conjugate targeting ovarian cancer. In 34 patients analyzed, the overall response rate was 24%, with 44% of patients remaining on treatment for over 16 weeks. Results from a data cut-off of Aug. 31, 2020, indicate a disease control rate of 60% for patients treated for 12 weeks or more. The company plans to initiate a dose expansion trial in less heavily pretreated ovarian cancer patients in Q4 2020.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's presentations at two upcoming investor conferences this September. The Wells Fargo Virtual Healthcare Conference will occur on Sept. 10, 2020, at 2:00 p.m. EDT, while the Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for Sept. 15, 2020, at 11:20 a.m. EDT. Webcasts of both events will be available on Sutro's website, with archived replays accessible for 30 days post-event. Sutro is focused on developing next-generation oncology therapeutics through innovative protein engineering.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
